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Abstract: Studies on sirtuins (SIRT), a family of proteins with deacetylase activity, have provided convergent 
evidence of the key role of these enzymes in aging-linked physiological functions. The link between SIRT1 and lon-
gevity has emerged in model organism but few data are available in humans, in particular relying on longitudinal 
studies. Here, we assessed whether a genetic variant within SIRT1 gene promoter (rs12778366) was associated 
to human longevity. We analyzed 586 genomic DNA (gDNA) collected in the study “Treviso Longeva” (TRELONG), 
including elderly over 70 years of age from the municipality of Treviso, a town in the Northeast of Italy, with a 11-year 
follow-up. We genotyped SIRT1 rs12778366 by real-time polymerase chain reaction (RT-PCR) allelic discrimination 
assay. A cross-sectional analysis performed by comparing people over and under 85 years of age did not evidence 
association between rs12778366 and longevity. When we performed a longitudinal analysis considering mortality 
as dependent variable, we did not observe an association of rs12778366 with longevity in the whole population 
(corrected P-value = 0.33). However, when we stratified the TRELONG subjects according to circulating level of inter-
leukin-6 (IL-6), a predictor of disability and mortality, we found that rs12778366 (TC+CC) carriers were at increased 
risk of mortality in comparison to the TT reference group (corrected P-value = 0.03, HR 1.47). Our data do not sup-
port a major role of rs12778366 in human longevity, but the stratified analysis on IL-6 suggests that this variant may 
be involved in the detrimental effect of high circulating IL-6 in the elderly. 
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Introduction
Human sirtuins (SIRTs) are a 7-member protein 
family sharing NAD+-dependent deacetylase 
activity. Sirtuins’ targets are transcription fac-
tors or structural proteins that are relevant for 
basic physiologic mechanisms, longevity and 
age-linked diseases [1, 2]. The most studied 
SIRT is SIRT1, a nuclear protein involved in 
longevity in model organism, and relevant 
for defensive mechanisms against oxidative 
stress, inflammation and cancer also in humans 
[3-8]. Genetic variants of SIRT1 have been 
studied in the field of human longevity with no 
univocal results. Flachsbart et al. compared 
German long-lived individuals (mean age: 98.3 
years) with younger subjects (mean age: 67.2 
years) by using a tag-SNP study design with 
negative results [9]. A similar conclusion was 
drawn by two other European studies (the 
Leiden 85-Plus study [10] and the Rotterdam 
study [11]) and by another study in Askenazi 
Jews [12]. However, positive association of 
SIRT1 with longevity-related traits or longevity 
were reported. Shimoyama et al. found an asso-
ciation between SIRT1 genetic variants, body 
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fat and blood pressure [13], while in a Dutch 
population carriers of the C-minor allele of 
rs12778366 (T/C) SIRT1 promoter variant had 
a significantly reduced mortality risk compared 
to the T-carriers, an effect that was gender-
independent and present even in smokers and 
overweight/obese subjects [14]. So, it is possi-
ble that SIRT1 modulates long-term survival or 
at least basic physiologic features relevant for 
longevity in humans.
Starting from the latter positive association, we 
decided to assess the role of rs12778366 in 
an ongoing prospective study enrolling an 
elderly population (TRELONG study) [15].
Materials and methods
Population 
The TRELONG study has been described in 
details elsewhere [15]. The study design envi-
sioned the selection of the 13,861 Treviso 
inhabitants over 70 years of age from the resi-
dents listed in the Registry Office of Treviso, the 
systematic sampling planning to include at 
least 100 participants according to gender and 
10-year-age group up to 100 years, and all 
available people > 100. A total of 668 partici-
pants were selected, 311 men and 357 women 
(mean age 84.0 ± 8.0 years, range 70.0-105.5 
years). A 11-year follow-up was then performed. 
A blood sample was collected and each partici-
pant was administered a structured interview 
assessing clinical, lifestyle and demographic 
information. The study protocol, blood collec-
tion procedure and the questionnaire to be 
administered at home were submitted to and 
approved by the ethical committee of the 
National Institute on Research and Care of 
the Elderly (INRCA, Italy). The protocol included 
an written informed consent for clinical and 
genetic studies. 
Biological samples preparation and SIRT1 
rs12778366 genotyping
Fasting peripheral blood samples (30 mL) were 
collected by venipuncture; one aliquot was 
used to separate mononuclear cells (PBMC) by 
a standard Ficoll centrifugation procedure. 
PBMC pellets were washed with ice-cold PBS, 
divided into aliquots and stored at -80°C for 
further analysis. From the enrolled population 
of 668 subjects, 590 gave their consent to 
blood collection and PBMC preparation. 
Genomic DNA was extracted from PBMC pellet 
using a vacuum-based semi-automated nucleic 
acid extractor (AB6100, Applied Biosystems, 
Foster City, CA, USA), checked for concentra-
tion by a UV-spectrophotometer (Eppendorf, 
Hamburg, Germany) and stored at 4°C. 
To assess rs12778366, a gDNA aliquot (about 
20 ng) was used in an allelic discrimination 
assay using a real-time PCR apparatus and 
TaqMan technology according to the manufac-
turer’s instructions (Applied Biosystems, Foster 
City, CA). The successful genotyping rate was 
around 99.3% (586 genotypes/590 available 
samples). Subjects’ genotypes were indepen-
dently confirmed in a random sample repre-
senting 10% of the population, with 100% 
replication rate.
Statistical analysis
Genotypic and allelic frequency distributions 
and departure from Hardy-Weinberg equilibri-
um were assessed by χ2-test. Calculations were 
done using GraphPad Prism program ver. 5.04. 
Survival curves were estimated by the Kaplan-
Meier method. Hazard ratios (HR) were calcu-
lated using Cox proportional hazard model. The 
proportional hazard has been tested using 
Schoenfeld’s residuals test, and it has never 
been rejected, thus confirming the suitability of 
the model. Multivariate regression analysis was 
performed considering mortality as dependent 
variable. These statistic analyses were comput-
ed using the package “survival” of the “R” soft-
ware. After correction for possible confounders 
(diabetes, cardiovascular diseases, cerebral 
vasculopaties, cancer, cholesterol level, educa-
tion, age and gender), results were considered 




In the whole population, rs12778366 genotyp-
ic distribution respected the Hardy-Weinberg 
equilibrium (HWE) (P=0.89, for χ2-test assess-
ing departure from HWE). We began evaluating 
the correlation of SIRT1 rs12778366 with lon-
gevity by splitting the TRELONG population 
around 85 years of age, starting from the 
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assumption that people over 85 years might be 
informative and considered as long-living sub-
jects, as supported also by previous evidence 
from the TRELONG study itself [16, 17]. Results 
of this analysis are shown in Table 1. Genotypic 
and allelic frequenciesdid not differ between 
the two groups, even when we combined the TC 
and CC carriers to increase sample size. We 
tried also to stratify according to gender, found-
ing no association (data not shown).
Prospective analysis
To take advantage from the prospective design 
of the TRELONG study, we analyzed rs12778366 
considering mortality as dependent variable. 
The last available vital status of the TRELONG 
study is reported in Table 2. Dead participants 
showed a significant risk profile in comparison 
to living people, including male gender, cogni-
tive decline (as indicated by reduced mean 
mini-mental state examination -MMSE-score), 
and increased mean circulating level of the pro-
inflammatory cytokine interleukin-6 (IL-6), that 
can be considered a marker of disability and 
mortality [18]. When we plot survival curves 
according to the SNP genotype, due to the low 
frequency of C-allele, we grouped TC and CC 
carriers in a dominant effect model hypothesis 
(Figure 1A), also basing on reported analysis 
[14]. As mortality might be influenced by sever-
al other variables, we controlled for TRELONG 
prevalent disorders (diabetes, cardiovascular 
diseases, cerebral vasculopaties and cancer), 
Table 1. Cross-sectional analysis of the genotypic and allelic frequencies of SIRT1 single nucleotide 
polymorphisms rs12778366 in the TRELOONG population
SNP (no.)
Genotype no. (%) Allele no. (%)
≤ 85 y > 85 y χ2 statistics ≤ 85 y > 85 y χ2 statistics
rs12778366 (n=586) TT 261 (80.1) 201 (77.3) χ2=0.72 T 583 (89.4) 458 (88.1) χ2=0.56
TC 61 (18.7) 56 (21.5) d.f.=2 C 69 (10.6) 62 (11.9) d.f.=1
CC 4 (1.2) 3 (1.2) P=0.69 P=0.45 
rs12778366 dominant model (n=586) TT 261 (80.1) 201 (77.3) χ2=0.65
TC+CC 65 (19.9) 59 (22.7) d.f.=1
P=0.41
Abbreviations: no.; number; 85 y: 85 years of age; d.f, degree of freedom; P: P-value.
Table 2. Characteristics of participants to the TRELONG study at baseline (2003) by vital status on 
April 2nd, 2014
Status on April 2nd. 2014 Alive Dead P-value 
Mean ± SD or % Mean ± SD or %
Number (%) 214 (32.04%) 454 (67.96%)
Males. n (%) 84 (39.25%)  227 (50.00%) 0.012
Age. median (range) (years) 76.90 (73.60-81.45) 88.20 (80.93-92.88) < 0.0001
BMI (kg/m2) 25.65 ± 4.02 24.31 ± 4.11 0.0001
BMI < 18.5 (underweight) 1.4% 7.5% 0.003
18.5 ≤ BMI < 25 (normal weight) 42.52% 43.61% 0.856
25 ≤ BMI < 30 (overweight) 41.12% 29.74% 0.005
BMI > 30 (obese) 12.62% 8.15% 0.091
Smoking status smoking (1) 41.12 41.41% 1.0
Never smoking (0)
SPPB 7.995 ± 3.57 4.115 ± 3.57 < 0.0001
CCI 4.439 ± 1.43 6.392 ± 1.96 < 0.001
MMSE ≤ 24. n (%) 31 (14.49%)  183 (46.26%) < 0.0001
APOE ε4/4 and 4/3. n (%) 27 (15.00%) 66 (16.92%) 0.649
IL-6 median (range) (pg/mL) 0.59 (0.33-1.30) 1.12 (0.54-2.61) < 0.001
BMI: body mass index; SPPB: short physical performance battery score; CCI: Charlson co-morbidity index; APOE: apolipoprotein 
E; IL-6: interleukin-6.
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risk factors (cholesterol level, education), age 
and gender. We found no association between 
rs12778366 and survival. In fact, by consider-
ing the TT-homozygous carriers group as refer-
ence, the hazard ratio (HR) and confidence 
interval (CI) of the TC+CC group was 1.12 
(0.88-1.43), with associated P-value =0.3. 
To investigate whether we had a different 
outcome in males or females, we performed 
a gender-stratified analysis, correcting for all 
the variables influencing survival listed above 
and considering TT-carriers as reference. 
Survival plots of the TRELONG population 
according to gender are shown in Figure 1B, 
rs12778366 polymorphism did not correlate 
with different mean values of continuous varia-
bles (systolic blood pressure level of TT carriers 
vs. TC+CC carriers: 144.6 ± 19.8 and 143.0 ± 
20.0 mmHg, respectively, P=0.33; fasting 
glucose level for TT carriers vs. TC+CC carri- 
ers: 106.3 ± 33.3 and 102.3 ± 32.1 mg/dL, 
respectively, P=0.25). Finally, we stratified the 
population according to the circulating level of 
interleukin-6 (IL-6). We found an increased 
mortality in TC+CC carries in comparison to TT 
reference group in the high IL-6 sub-population 
(considering as cut-off value IL-6 plasma level ≥ 
0.93 pg/mL) (Table 3). 
Figure 1. Survival curves of the TRELONG population according to rs12778366 
genotype. A. Survival plot of the whole TRELONG population, considering the 
TT group as reference vs. the TC+CC carriers. The reported P-value was cor-
rected for possible confounding factors affecting longevity (age, gender, edu-
cation level, cholesterol level, cardiovascular disease, vascular cerebropaties, 
diabetes and cancer). B, C. Survival plots of the TRELONG population stratified 
according to rs12778366 genotype and gender. The associated P-value was 
corrected as above. 
1C. We had no significant 
effect, as in males the HR 
(CI) was 1.13 (0.81-1.59), 
with associated P-value of 
0.55; in females it was 1.1 
(0.78-1.56), with P-value of 
0.45. 
These results did not rule 
out that the effect of 
rs12778366 may be rele-
vant for a TRELONG pop- 
ulation component group. 
To verify this hypothesis, we 
stratified the study acco- 
rding to parameters that 
were significantly different 
between alive and dead 
subjects (Table 2), as body 
mass index (BMI), blood 
pressure or fasting glu- 
cose level, (considering as 
overweight/obese people 
with BMI > 25), a cogni- 
tive performance measure 
(MMSE, cut-off for cognitive 
impairment < 24) [19], or 
measures of disability and 
frailty, as the short physical 
performance battery (SP- 
PB) score (cut-off value of 
6) and the Charlson co-
morbidity index (CCI) (cut-
off score of 6) [15]. The 
results are summarized in 
Table 3. We were not able 
to highlight a significant 
variation in the HRs of the 
considered features. More- 
over, the presence of the 
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Discussion
The contribution to human longevity of genetic 
variants of SIRT1 is a matter of debate and the 
overall negative results suggest that in humans 
the relevance of this component on a so 
complex phenotype may be limited or hard to 
highlight. We addressed a specific aspect of 
SIRT1 variability (rs12778366) in relation to 
longevity, starting from available evidence [14], 
and despite our robust prospective design 
we were unable to find an association in the 
entire TRELONG population or after stratifica-
tion according to glucose fasting level, analysis 
performed in an attempt to parallel what re- 
ported by Figarska et al [14]. We acknowledge 
that the TRELONG population is different from 
that enrolled in the above cited study, as the 
TRELONG design was centered on elderly sub-
jects while Figarska et al. followed for 18 years 
a general population-based cohort. This differ-
ence may be relevant, as it suggests that the 
positive effect of this variant on human longev-
ity and health status is age-dependent and may 
magnify its action in a defined age bracket, a 
situation that is not uncommon [20]. In fact, a 
similar scenario was reported for instance for 
dementia, where some relevant risk factors (i.e. 
BMI or apolipoprotein E genotype) may vary 
their association or magnitude effect when 
assessed in a younger population or in the 
elderly [21, 22].
deal with systemic inflammation [23, 24] and 
more directly with IL-6 as SIRT1 regulates the 
acetylation state of NF-kB, a transcription 
factor promoting IL-6 expression [25, 26]. 
Consequently, in the TRELONG patients having 
the rs12778366 C-variant and increased val-
ues of  circulating IL-6, rs12778366 may be an 
additional risk factor contributing to mortality 
by acting on SIRT1 protein level that in turn is 
related to the NF-kB/IL-6 expression pattern. 
A direct measure of SIRT1 mRNA level in 
TRELONG patients may help in assessing this 
hypothesis and supporting a functional corr- 
elation between SIRT1 rs12778366 C-variant 
and SIRT1 transcription. Unfortunately, we did 
not have suitable material to perform this 
analysis.
In summary, we were unable to confirm in an 
Italian elderly population the reported effect of 
rs12778366 on human longevity, but we found 
some evidence that SIRT1 promoter genetic 
variability may have a different impact on 
survival and health status in aged people in 
comparison to younger ones.
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Table 3. Stratified longitudinal analysis of mortality in the TRELONG 
population. Hazard ratio (HR) for mortality calculated according to 
rs12778366 genotype and smoking status, BMI, SPPB, CCI, MMSE and 
circulating IL-6. TT-carriers were considered as reference. The reported 
P-values were corrected for age, gender, education level, cholesterol le- 
vel, cardiovascular disease, vascular cerebropaties, diabetes and cancer
Stratification HR (95% CI) P-value
BMI < 18.5 1.016 (0.403-2.563) 0.973
18.5 ≤ BMI < 25 1.165 (0.820-1.656) 0.393
25 ≤ BMI < 30 and BMI ≥ 30 0.916 (0.605-1.389) 0.680
SPPB score < 6 1.272 (0.968-1.671) 0.085
SPPB score ≥ 6 0.793 (0.478-1.316) 0.370
CCI < 6 1.149 (0.839-1.573) 0.386
CCI ≥ 6 1.104 (0.763-1.597) 0.600
MMSE ≤ 24 1.232 (0.868-1.748) 0.243
MMSE > 24 1.065 (0.766-1.480) 0.707
IL-6 < 0.93 (pg/mL) 0.948 (0.650-1.382) 0.780
IL-6 ≥ 0.93 (pg/mL) 1.476 (1.038-2.098) 0.030
BMI: body mass index; SPPB: short physical performance battery score; CCI: Charlson 
comorbidity index; MMSE: mini-mental state examination; IL-6: interleukin-6.
The above interpreta-
tion of our finding of 
no association between 
SIRT1 rs12778366 and 
longevity may also be 
the right key to interpret 
the increased mortality 
of TRELONG subjects 
having the rs12778366 
C-allele and elevated 
levels of IL-6. This 
cytokine is a marker of 
disability and mortality 
whose detrimental eff- 
ect has already been 
described in the study 
[18], and is supportive 
of a general pro-infl- 
ammatory background 
with aging and disease. 
SIRT1 genetic variability 
and enzymatic function 
have been reported to 
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